Screener
Zevra Therapeutics, Inc. ZVRA Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001434647-26-000068
| Line item | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Purchases of investments | (80,836) | (157,712) |
| Sales and maturities of investments | 143,222 | 30,500 |
| Proceeds from sale of PRV | — | 150,000 |
| Net cash provided by investing activities | 111,069 | 22,476 |
| Cash flows from financing activities: | ||
| Repayment of debt | (60,092) | — |
| Payments for employee taxes related to stock awards | (1,485) | — |
| Proceeds from Employee Stock Purchase Plan | 434 | 413 |
ITEM 1.FINANCIAL STATEMENTS
FAQ
- What is Zevra Therapeutics, Inc.'s investing cash flow?
- Zevra Therapeutics, Inc. (ZVRA) reported investing cash flow of $31.45M in Q2 2026.
- How has Zevra Therapeutics, Inc.'s investing cash flow changed year-over-year?
- Zevra Therapeutics, Inc.'s investing cash flow increased by 163.5% year-over-year, from $11.93M to $31.45M.
- What is the long-term trend for Zevra Therapeutics, Inc.'s investing cash flow?
- Over 2 years (2021 to 2024), Zevra Therapeutics, Inc.'s investing cash flow has grown at a 19.5% compound annual growth rate (CAGR), from -$15.52M to -$22.16M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Zevra Therapeutics, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude